BioStock: CombiGene welcomes AmbioPharm as CDMO in pain project

CombiGene has entered into a partnership with AmbioPharm, a US-based contract manufacturer for the COZY01 peptide-based pain project, jointly undertaken with Zyneyro. With extensive experience in peptide development and manufacturing, AmbioPharm meets all regulatory criteria, setting the stage for toxicology studies and human studies. AmbioPharm's ability for commercial production also positions them as a potential long-term partner in the COZY01 venture.

Read the article at biostock.se:

https://www.biostock.se/en/2023/09/combigene-welcomes-ambiopharm-as-cdmo-in-pain-project/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/